Company intelligence / Profile preview
FUJIFILM Holdings
- Ownership
- Private
- Employees
- ~70000
- Development stage
- Other
Overview
Fujifilm's Life Sciences division supports drug development from discovery to commercialization, including clinical trials in oncology and infectious diseases; favipiravir (RNA polymerase inhibitor) received Japanese approval for SFTS in June 2024[6].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeLiposomeLipid nanoparticlemRNA-based drugsMonoclonal antibodyRecombinant proteinCytokineInduced pluripotent stem cell derived therapyVaccine
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on FUJIFILM Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FUJIFILM Holdings.